Inhibikase Therapeutics News and Activities

Inhibikase Therapeutics is a company listed under the stock ticker IKT (US).

View the org chart displaying its 18 main executives

Most searched biographies at Inhibikase Therapeutics

• Mark Iwicki, Chief Executive Officer
• Roberto Bellini, Director
• Vincent Aurentz, Director

Create your alert
to follow the executive moves at Inhibikase Therapeutics.

Inhibikase Therapeutics has 2,426 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• Archimed Group has acquired Esperion Therapeutics (posted on July 14 2026).
• The new name of ChemoTech is Neem’s Hill. (posted on July 14 2026).
• MindRank has just announced a $52 Million fundraising (posted on July 14 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Robert Gould - Board Member at Fulcrum Therapeutics

Learn more about the Biotechnology industry

Press releases by Inhibikase Therapeutics

• Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity
• Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension
• Press Releases
• Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity
• Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension
• Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
• Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
• Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity
• View more press releases Close

Social media about Inhibikase Therapeutics

• Inhibikase Therapeutics on Wikipedia, Google News & Yahoo Finance
• Inhibikase Therapeutics on LinkedIn, X (Twitter) & YouTube